Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  12/16/2011
 
Trade Name:  Maxalt and Maxalt-MLT
 
Generic or Proper Name (*):  rizatriptan
 
Indications Studied:  Treatment of migraine
 
Therapeutic Category:  Antimigraine
 
Ages Studied:  6 - 17 years
 
Study #:  1
 
Study Type:  Safety/Pharmacokinetic/Tolerability
 
Study Design:  Open Label
 
No Patients:  31
 
BPCA(B), PREA(P):  B
 
Unknown:  0
 
-
-